These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 37273421)

  • 1. Epigenetic targets in B- and T-cell lymphomas: latest developments.
    Ribeiro ML; Sánchez Vinces S; Mondragon L; Roué G
    Ther Adv Hematol; 2023; 14():20406207231173485. PubMed ID: 37273421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging epigenetic-modulating therapies in lymphoma.
    Sermer D; Pasqualucci L; Wendel HG; Melnick A; Younes A
    Nat Rev Clin Oncol; 2019 Aug; 16(8):494-507. PubMed ID: 30837715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
    Hassler MR; Schiefer AI; Egger G
    Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.
    Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G
    Front Genet; 2019; 10():986. PubMed ID: 31681423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
    Serganova I; Chakraborty S; Yamshon S; Isshiki Y; Bucktrout R; Melnick A; Béguelin W; Zappasodi R
    Front Cell Dev Biol; 2021; 9():805195. PubMed ID: 35071240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma.
    Smith MR
    Curr Probl Cancer; 1996; 20(1):6-77. PubMed ID: 8919170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
    Chung C
    Blood Lymphat Cancer; 2022; 12():99-106. PubMed ID: 35959380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Products Impacting DNA Methyltransferases and Histone Deacetylases.
    Akone SH; Ntie-Kang F; Stuhldreier F; Ewonkem MB; Noah AM; Mouelle SEM; Müller R
    Front Pharmacol; 2020; 11():992. PubMed ID: 32903500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas.
    Hosing C; Champlin RE
    Ann Oncol; 2011 Jul; 22(7):1471-1477. PubMed ID: 21551006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
    Reyes-Garau D; Ribeiro ML; Roué G
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
    Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
    Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases.
    Quintanilla-Martínez L; Lome-Maldonado C; Ott G; Gschwendtner A; Gredler E; Reyes E; Angeles-Angeles A; Fend F
    Blood; 1997 Jan; 89(2):644-51. PubMed ID: 9002968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical advances in epigenetic therapies for lymphoma.
    Rosenthal AC; Munoz JL; Villasboas JC
    Clin Epigenetics; 2023 Mar; 15(1):39. PubMed ID: 36871057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
    Mihaila RG
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
    Ji J; Liu Z; Kuang P; Dong T; Chen X; Li J; Zhang C; Liu J; Zhang L; Shen K; Liu T
    Int J Cancer; 2021 Dec; 149(12):2075-2082. PubMed ID: 34398971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.